ACS Synthetic BiologySynthetic BiologyPeer-reviewed journal article
Optimizing a CRISPR-Cas13d gene circuit for tunable target RNA downregulation with minimal collateral RNA cutting
Yiming WaniD, Christopher HelenekiD, Damiano Coraci, Gábor BalázsiiD
Abstract
The invention of RNA-guided DNA cutting systems has revolutionized biotechnology. More recently, RNA-guided RNA cutting by Cas13d entered the scene as a highly promising alternative to RNA interference to engineer cellular transcriptomes for biotechnological and therapeutic purposes. Unfortunately, "collateral damage" by indiscriminate off-target cutting tampered enthusiasm for these systems. Yet, how collateral activity, or even RNA target reduction depends on Cas13d and guide RNA abundance has remained unclear due to the lack of expression-tuning studies to address this question. Here we use precise expression-tuning gene circuits to show that both nonspecific and specific, on-target RNA reduction depend on Cas13d and guide RNA levels, and that nonspecific RNA cutting from trans cleavage might contribute to on-target RNA reduction. Using RNA-level control techniques, we develop new Multi-Level Optimized Negative-Autoregulated Cas13d and crRNA Hybrid (MONARCH) gene circuits that achieve a high dynamic range with low basal on-target RNA reduction while minimizing collateral activity in human kidney cells and green monkey cells most frequently used in human virology. MONARCH should bring RNA-guided RNA cutting systems to the forefront, as easily applicable, programmable tools for transcriptome engineering in biotechnological and medical applications.
- organism: human
- organism: non-human primate
- assay: CRISPR screen
- research focus: perturbation response prediction
- approach: experimental assay
- Citations
- 5
- FWCI
- 0.68
- Field percentile
- top 36%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Low copy CRISPR-Cas13d mitigates collateral RNA cleavage
Sydney K. Hart, Simon Müller, … Neville E. Sanjana·Nature BiotechnologyPeer-reviewed·Feb 11, 2025
- Negative autoregulation mitigates collateral RNase activity of repeat-targeting CRISPR-Cas13d in mammalian cells
Chase P. Kelley, Maja C. Haerle, Eric T. Wang·Cell ReportsPeer-reviewed·Aug 1, 2022
- High-fidelity Cas13 variants for targeted RNA degradation with minimal collateral effect
Huawei Tong, Jia Huang, … Hui Yang·Nature BiotechnologyPeer-reviewed·Aug 11, 2022
- Deep learning and CRISPR-Cas13d ortholog discovery for optimized RNA targeting
J. Wei, P. Lotfy, … S. Konermann·bioRxiv·Sep 14, 2021
- CRISPR/Cas13 effectors have differing extents of off-target effects that limit their utility in eukaryotic cells
Yuxi Ai, Dongming Liang, Jeremy E. Wilusz·Nucleic Acids ResearchPeer-reviewed·Feb 21, 2022
- Cytosolic CRISPR RNA for RNA-targeting CRISPR-Cas systems
Ezra C.K. Cheng, Jodie Lam, S. Chul Kwon·EMBO ReportsPeer-reviewed·Feb 26, 2025